Home>Topics>>Lucrative Opportunities In Amarin's Options Market

Lucrative Opportunities In Amarin's Options Market

Healthcare Sector and Stocks Analysis from Seeking Alpha

Mon, 26 Nov 2012

By Brian L. Wilson : Although the arguments between Amarin (NASDAQ: AMRN ) bulls and bears are starting to become quite stale due to a lack of information about the NCE (New Chemical Entity) status of their flagship drug Vascepa from the FDA (many months after approval, which is rare). There is ...
Content Partners